Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.42 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | FRK | P42685 | 2/20 | 0.42 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017114 | 0.81 | KDM4E (0.41) | PTGS2PTGS1MAPK8MAPK9CSNK1D | |
| SCHEMBL637327 | 0.70 | TDP1 (0.55) | KDM4ESMN1; SMN2ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL976669 | 0.66 | PIK3CD (0.47) | PTGS2PTGS1MAPK8MAPK9CSNK1D | |
| SCHEMBL2041772 | 0.66 | GRM5 (0.41) | KDM4EHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL2338659 | 0.64 | MAPK1 (0.65) | MAPK1CYP1A2TDP1ALOX12ALOX15 | |
| SCHEMBL13551557 | 0.63 | KDR (0.45) | KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL6890415 | 0.63 | KDM4E (0.41) | KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL3762990 | 0.63 | ALDH1A1 (0.56) | KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL14842599 | 0.63 | ALDH1A1 (0.42) | KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL1339860 | 0.62 | CYP1A2 (0.47) | KDM4EHPGDSMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403847-B2 | Substituted heteroaryl fused derivatives as P13K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759359-B2 | Substituted heteroaryl fused derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-08-04 | — | — | US | disclosed |
| WO-2011075643-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190319-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | PTGS2 925/4885PTGS1 776/4885MAPK8 310/4885 |
| US-20140275127-A1 | SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3R5 | PTGS2 925/4885PTGS1 776/4885MAPK8 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.